Acquisition Completed
BioCryst Pharmaceuticals acquisition of Astria Therapeutics
US$700m enterprise value
Announced 14 Oct 2025
Advisers
BioCryst Pharmaceuticals
Acquirer
- Financial adviser
- Legal adviser
- Target
- Astria Therapeutics
- Acquirer
- BioCryst Pharmaceuticals
- Target based in
- United States
- Buyer based in
- United States
- Completed
- 23 Jan 2026
- Sector
- Biotech
- Tags
- Biotech, Rare Disease, Drug Development
In the league tables
- M&A financial advisers, Calendar 2025 Evercore #3 · BofA Securities #9
- M&A financial advisers, completed, 2026 to date BofA Securities #3 · Evercore #4
- M&A legal advisers, Calendar 2025 Sidley Austin #5 · Covington & Burling #13
- M&A legal advisers, completed, 2026 to date Covington & Burling #8 · Sidley Austin #13
Similar deals
- Jazz Pharmaceuticals acquisition of Actio Biosciences Aug 2026 · US$820m · Biotech
- Werewolf Therapeutics and Ambros Therapeutics merger Aug 2026 · US$500m · Biotech
- Incyte acquisition of Vega Therapeutics Jun 2026 · US$1.3bn · Biotech
- Servier acquisition of Sevasemten and Edgewise muscular dystrophy business Jun 2026 · US$1.6bn · Biotech
- BioMarin Pharmaceutical acquisition of Alesta Therapeutics Aug 2026 · US$275m · Biotech



